COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
Authors:
- Perrine VuagnatPVPerrine Vuagnat
- Maxime FrelautMFMaxime Frelaut
- Toulsie RamtohulTRToulsie Ramtohul
- Clémence BasseCBClémence Basse
- Aurélien NoretANAurélien Noret
- Audrey BellesoeurABAudrey Bellesoeur
- Vincent ServoisVSVincent Servois
- Delphine HequetDHDelphine Hequet
- Enora LaasELEnora Laas
- Youlia KirovaYKYoulia Kirova
- Luc CabelLCLuc Cabel
Preprint
Abstract
Background: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). Methods: An IRB-approved prospective registry was set up at ICH for all breast cancer patients with COVID-19 symptoms or radiologic signs. Results: Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (>70) were the two factors associated with a higher risk of intensive care unit admission and/or death. Conclusions: This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe SARS-CoV-2 infection in breast cancer patients.Keywords
All Related Versions
- Published version: Breast Cancer Research, 22 (1), 1.
This publication has 11 references indexed in Scilit:
- Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York CityAnnals of Oncology, 2020
- Timely Diagnosis and Treatment Shortens the Time to Resolution of Coronavirus Disease (COVID-19) Pneumonia and Lowers the Highest and Last CT Scores From Sequential Chest CTAmerican Journal of Roentgenology, 2020
- SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, ChinaJAMA Oncology, 2020
- Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 PatientsAmerican Journal of Roentgenology, 2020
- Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, ChinaAnnals of Oncology, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020
- SARS-CoV-2 transmission in cancer patients of a tertiary hospital in WuhanmedRxiv, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort studyPLOS Medicine, 2019
- A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysisRadiotherapy and Oncology, 2004